

## Data Sharing Statement

Heudel. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor–Positive Recurrent or Metastatic Endometrial Cancer. *JAMA Oncol*. Published May 12, 2022. doi:10.1001/jamaoncol.2022.1047

### Data

**Data available:** No

### Additional Information

**Explanation for why data not available:** The data that support the findings of this study are not publicly available. Data contain information that could compromise privacy of the research participants.